TKUN Stock Overview
Engages in the cultivation, production, marketing, storage, distribution, export and import, and sale of cannabis-based products in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Tikun Olam-Cannbit Pharmaceuticals Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.42 |
| 52 Week High | ₪0.57 |
| 52 Week Low | ₪0.23 |
| Beta | 0.88 |
| 1 Month Change | 9.19% |
| 3 Month Change | 23.44% |
| 1 Year Change | 26.83% |
| 3 Year Change | -85.30% |
| 5 Year Change | -95.23% |
| Change since IPO | -99.98% |
Recent News & Updates
Tikun Olam-Cannbit Pharmaceuticals Ltd's (TLV:TKUN) Popularity With Investors Under Threat As Stock Sinks 26%
Dec 02
Health Check: How Prudently Does Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Use Debt?
Oct 23Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Has Debt But No Earnings; Should You Worry?
Jun 21Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV:TKUN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 28Recent updates
Tikun Olam-Cannbit Pharmaceuticals Ltd's (TLV:TKUN) Popularity With Investors Under Threat As Stock Sinks 26%
Dec 02Health Check: How Prudently Does Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Use Debt?
Oct 23Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Has Debt But No Earnings; Should You Worry?
Jun 21Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV:TKUN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 28Risks To Shareholder Returns Are Elevated At These Prices For Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV:TKUN)
Jul 21Would Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Be Better Off With Less Debt?
Oct 03Is Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Weighed On By Its Debt Load?
Jun 03Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Is Carrying A Fair Bit Of Debt
Oct 17Is Tikun Olam - Cannbit Pharmaceuticals (TLV:TKUN) Using Debt Sensibly?
May 19Shareholders Of Tikun Olam - Cannbit Pharmaceuticals (TLV:TKUN) Must Be Happy With Their 135% Total Return
Mar 19How Much Did Tikun Olam - Cannbit Pharmaceuticals'(TLV:TKUN) Shareholders Earn From Share Price Movements Over The Last Five Years?
Dec 02
Shareholder Returns
| TKUN | IL Pharmaceuticals | IL Market | |
|---|---|---|---|
| 7D | 45.5% | -0.9% | 1.6% |
| 1Y | 26.8% | -11.0% | 30.1% |
Return vs Industry: TKUN exceeded the IL Pharmaceuticals industry which returned -11% over the past year.
Return vs Market: TKUN underperformed the IL Market which returned 30.1% over the past year.
Price Volatility
| TKUN volatility | |
|---|---|
| TKUN Average Weekly Movement | 10.1% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in IL Market | 7.9% |
| 10% least volatile stocks in IL Market | 3.0% |
Stable Share Price: TKUN's share price has been volatile over the past 3 months compared to the IL market.
Volatility Over Time: TKUN's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2023 | 50 | Ronen Elad | www.tikun-olam.org.il |
Tikun Olam-Cannbit Pharmaceuticals Ltd engages in the cultivation, production, marketing, storage, distribution, export and import, and sale of cannabis-based products in Israel. The company provides medical cannabis products for the treatment and relief of symptoms in a wide variety of medical indications. It also offers training and patient care services.
Tikun Olam-Cannbit Pharmaceuticals Ltd Fundamentals Summary
| TKUN fundamental statistics | |
|---|---|
| Market cap | ₪33.66m |
| Earnings (TTM) | -₪50.05m |
| Revenue (TTM) | ₪42.55m |
0.8x
P/S Ratio-0.7x
P/E RatioIs TKUN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TKUN income statement (TTM) | |
|---|---|
| Revenue | ₪42.55m |
| Cost of Revenue | ₪38.87m |
| Gross Profit | ₪3.67m |
| Other Expenses | ₪53.72m |
| Earnings | -₪50.05m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.62 |
| Gross Margin | 8.63% |
| Net Profit Margin | -117.64% |
| Debt/Equity Ratio | 215.1% |
How did TKUN perform over the long term?
See historical performance and comparison